long intergenic non-protein coding RNA 2831Genealiases: []
Q-omics provides the consensus-scored LINC02831 profile across patient tissues and cancer cell-line models. LINC02831 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LINC02831 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, LINC02831 RNA expression shows 7,689 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UCEC, BRCA, and PDAC as cancer lineages where LINC02831 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02831 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02831 survival associations across molecular data types. LINC02831 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02831 RNA expression–survival associations across cancer types. High LINC02831 expression shows unfavorable associations in UCEC, THCA, KIRP, READ and LGG, but favorable associations in ACC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LINC02831 RNA expression.
This table summarizes LINC02831 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02831. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02831 shows lower tumor expression in KICH and KIRC and higher tumor expression in BRCA and LUSC. The BRCA box plot shows higher LINC02831 RNA expression in tumor versus normal tissue (log2 FC = +0.042, t-test p = .001).
This table shows molecular features associated with LINC02831 in patient tissues and cancer cell lines. In patient samples, LINC02831 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
